When big toe arthritis remains painful after several operations, the appeal of regenerative treatment is understandable. A reader with bilateral hallux rigidus has undergone four operations across the two feet and now faces fusion recommendations. Career demands make recovery difficult to arrange. The immediate hope is meaningful pain relief, even if it is temporary.
The first question is whether there is a treatable source of pain that an injection can reasonably address. The second is whether the proposed product has evidence for that particular problem. The term “stem cell therapy” alone answers neither question.
Previous surgery changes the treatment decision
An injection proposal should begin with the names of the previous procedures, operative reports, current imaging, and an examination. Pain from joint inflammation requires different consideration from painful hardware, implant failure, nerve irritation, or a bone-healing problem. Hallux rigidus is arthritis of the great-toe joint; it should not be treated as interchangeable with a bunion deformity. (1)
A useful consultation question is: “What do you think is hurting, and why would this injection help that structure?” Also ask how the clinician would recognize a problem requiring surgical reassessment before proceeding.
The direct human stem-cell evidence is very limited
A 2021 report described one 50-year-old man with grade-2 hallux rigidus treated with an autologous adipose-derived preparation. Pain and function improved during nine months of follow-up. This was a single case without a control group, involving fat-derived material rather than bone marrow, Wharton’s jelly, or cord blood. (2)
The report offers a reason for further study. It cannot estimate the chance of relief after multiple operations, establish cartilage restoration, or show that any other product has the same effect. The patient’s disease stage also differs from an assumed end-stage revision situation. A promising individual result is not a reliable forecast for another patient.
Bone marrow concentrate is a different preparation
Bone marrow concentrate is an autologous preparation made from the patient’s marrow. It contains a mixture of cells and other components; it is not a purified or culture-expanded stem-cell dose. When considering a proposal, ask for the exact preparation and evidence in the great-toe joint, especially after surgery.
The literature search for this update did not identify convincing controlled human evidence establishing bone marrow concentrate as a treatment for advanced postoperative hallux rigidus. Findings from knee arthritis or surgically repaired cartilage defects should not be presented as proof that a toe injection will rebuild the joint.
Why Wharton’s jelly is being investigated
Wharton’s jelly is the connective tissue surrounding blood vessels in the umbilical cord. Its matrix and signaling components have attracted research interest. Gupta and colleagues analyzed an umbilical-cord-derived preparation and reported components including hyaluronic acid, growth factors, and extracellular vesicles. This was a laboratory characterization study, not a hallux rigidus treatment trial. (3)
That research provides a biological rationale for investigation. It does not show that injecting donated tissue improves a painful great toe, replaces missing cartilage, or reverses postoperative mechanical changes. The authors’ commercial affiliations also belong in the interpretation of this early product research.
Processed donor matrix, cells isolated and expanded from cord tissue, and cord blood are different preparations. A commercial Wharton’s jelly product should not automatically be described as a viable stem-cell treatment.
Cord blood and exosomes: separate questions
Umbilical cord blood is blood collected from the cord; it is not Wharton’s jelly. Likewise, extracellular vesicles and exosomes are signaling particles, not stem cells. The research search did not identify controlled human trials demonstrating benefit from Wharton’s jelly, cord-blood products, or exosome injections for repeatedly operated hallux rigidus. They therefore remain investigational possibilities for this indication, rather than established substitutes for fusion.. (3)
FDA states that these regenerative medicine products have not been approved for orthopedic conditions. Manufacturer registration and a ClinicalTrials.gov listing do not establish approval or lawful marketing. For a proposed donor-derived or exosome treatment, ask about its exact regulatory status and applicable clinical-trial oversight. (4)
Where does PRP fit?
PRP uses the patient’s blood platelets and should be discussed separately from donor tissue and marrow preparations. A published hallux rigidus series combined PRP with resection arthroplasty and a resorbable implant in 45 patients. Improvement after the combined procedure does not establish the effectiveness of PRP injection alone. (5)
For this reader, meaningful outcomes might include tolerating a work shift, walking a specified distance, sleeping more comfortably, or reducing rescue medication. Record the starting point and agree on a follow-up interval. Paying for repeated procedures without measurable benefit is a reason to reassess the plan.
A temporary plan can also include footwear changes, activity adjustments, and appropriate medication review. The conservative-treatment literature shows variable results, so expectations should remain individual. (6)
Questions about an assessment can be directed through our contact page; this educational discussion does not establish candidacy or confirm that a particular product is offered.
References
1 Anderson MR, Ho BS, Baumhauer JF. Republication of “Current Concepts Review: Hallux Rigidus”. Foot Ankle Orthop. 2023;8(3):24730114231188123. doi:10.1177/24730114231188123.
2 Braile A, Toro G, De Cicco A, Cecere AB, Zanchini F, Schiavone Panni A. Hallux rigidus treated with adipose-derived mesenchymal stem cells: A case report. World J Orthop. 2021;12(1):51-55. doi:10.5312/wjo.v12.i1.51.
3 Gupta A, El-Amin SF, Levy HJ, Sze-Tu R, Ibim SE, Maffulli N. Umbilical cord-derived Wharton’s jelly for regenerative medicine applications. J Orthop Surg Res. 2020;15(1):49. doi:10.1186/s13018-020-1553-7.
4 U.S. Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies. Accessed November 20, 2026.
5 Siclari A, Krueger JP, Endres M, Boux E. A 24-month follow-up after treatment of hallux rigidus with resection arthroplasty in combination with a resorbable polymer-based implant and platelet-rich plasma. Foot Ankle Surg. 2018;24(5):389-393. doi:10.1016/j.fas.2017.04.007.
6 Acker AS, Mendes de Carvalho KA, Hanselman AE. Hallux Rigidus: Update on Conservative Management. Foot Ankle Clin. 2024;29(3):405-415. doi:10.1016/j.fcl.2023.09.010.
The post Stem Cells, PRP, and Wharton’s Jelly for Hallux Rigidus: What Is Realistic After Surgery? appeared first on Stem Cell Institute.